Lotus Pharmaceutical Overview
- Year Founded
-
1966
- Status
-
Public
- Employees
-
94
- Stock Symbol
-
1795
- Investments
-
7
- Share Price
-
$3.07
- (As of Friday Closing)
Lotus Pharmaceutical General Information
Description
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
Contact Information
Website
www.lotuspharm.comCorporate Office
- 17th Floor, Number 277
- Song Ren Road, Xin Yi District
- Taipei City, 110
- Taiwan
Corporate Office
- 17th Floor, Number 277
- Song Ren Road, Xin Yi District
- Taipei City, 110
- Taiwan
Lotus Pharmaceutical Stock Performance
As of 20-Nov-2026, Lotus Pharmaceutical’s stock price is $3.07. Its current market cap is $818M with 266M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.07 | $3.38 | $3.04 - $11.54 | $818M | 266M | 1.26M | $0.27 |
Lotus Pharmaceutical Financials Summary
As of 30-Sep-2026, Lotus Pharmaceutical has a trailing 12-month revenue of $984M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,128,654 | 2,594,397 | 2,438,152 | 2,635,693 |
| Revenue | 984,142 | 657,444 | 579,118 | 544,431 |
| EBITDA | 295,881 | 257,527 | 252,790 | 219,577 |
| Net Income | 70,394 | 151,304 | 157,851 | 131,810 |
| Total Assets | 3,485,855 | 3,394,362 | 1,219,473 | 1,073,665 |
| Total Debt | 1,577,462 | 1,518,083 | 415,597 | 377,011 |
Lotus Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lotus Pharmaceutical Patents
Lotus Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4374853-A1 | Solid formulation of enzalutamide | Inactive | 22-Nov-2022 | ||
| EP-4302755-A1 | Palbociclib formulation containing an amino acid | Active | 07-Jul-2022 | ||
| EP-4302755-B1 | Palbociclib formulation containing an amino acid | Active | 07-Jul-2022 | ||
| EP-4302832-A1 | Palbociclib formulation containing glucono delta lactone | Inactive | 07-Jul-2022 | ||
| EP-4260848-A1 | Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation | Inactive | 11-Apr-2022 | A61K9/2009 |
Lotus Pharmaceutical Signals
Lotus Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lotus Pharmaceutical Investments & Acquisitions (7)
Lotus Pharmaceutical’s most recent deal was a Merger/Acquisition with Sandoz Philippines for . The deal was made on 02-Apr-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sandoz Philippines | 02-Apr-2026 | Merger/Acquisition | Distributors (Healthcare) | ||
| Alvogen Group | 03-Dec-2025 | Merger/Acquisition | Drug Discovery | ||
| Duy Tan Pharmaceutical (Five Pharmaceutical Products in Vietnam) | 30-Sep-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Sanofi (Alphachymotrypsine Choay Business in Vietnam and Cambodia) | 07-Jan-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Teva Pharma (Thailand) Company | 06-Jun-2024 | Merger/Acquisition | Other Healthcare Services |
Lotus Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
26.07 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Lotus Pharmaceutical Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Alvogen Group | Morristown, NJ | 2007 |
Lotus Pharmaceutical FAQs
-
When was Lotus Pharmaceutical founded?
Lotus Pharmaceutical was founded in 1966.
-
Where is Lotus Pharmaceutical headquartered?
Lotus Pharmaceutical is headquartered in Taipei City, Taiwan.
-
What is the size of Lotus Pharmaceutical?
Lotus Pharmaceutical has 94 total employees.
-
What industry is Lotus Pharmaceutical in?
Lotus Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Lotus Pharmaceutical a private or public company?
Lotus Pharmaceutical is a Public company.
-
What is Lotus Pharmaceutical’s stock symbol?
The ticker symbol for Lotus Pharmaceutical is 1795.
-
What is the current stock price of Lotus Pharmaceutical?
As of 20-Nov-2026 the stock price of Lotus Pharmaceutical is $3.07.
-
What is the current market cap of Lotus Pharmaceutical?
The current market capitalization of Lotus Pharmaceutical is $818M.
-
What is Lotus Pharmaceutical’s current revenue?
The trailing twelve month revenue for Lotus Pharmaceutical is $984M.
-
What is Lotus Pharmaceutical’s annual earnings per share (EPS)?
Lotus Pharmaceutical’s EPS for 12 months was $0.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process